| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sophie Combaluzier, Julie Quessada, Norman Abbou, Robin Arcani, Antoine Tichadou, Jean Gabert, Régis Costello, Marie Loosveld, Geoffroy Venton, Yaël Berda-Hadda. Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells. vol 12. issue 6. 2023-03-29. PMID:36980287. |
myeloproliferative neoplasms (mpn) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. |
2023-03-29 |
2023-08-14 |
Not clear |
| Jennifer Mary O'Sullivan, Adam J Mead, Bethan Psail. Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood. vol 141. issue 4. 2023-01-30. PMID:36322938. |
myeloproliferative neoplasms (mpn) are a group of clonal stem cell-derived hematopoietic malignancies driven by aberrant janus kinase-signal transducer and activator of transcription proteins (jak/stat) signaling. |
2023-01-30 |
2024-02-12 |
human |
| Ayalew Teffer. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology. 2023-01-21. PMID:36680511. |
primary myelofibrosis (pmf) is a myeloproliferative neoplasm (mpn) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by jak2, calr, or mpl mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (emh), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival. |
2023-01-21 |
2023-08-14 |
Not clear |
| Ayalew Teffer. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. American journal of hematology. vol 96. issue 1. 2021-01-25. PMID:33197049. |
primary myelofibrosis (pmf) is a myeloproliferative neoplasm (mpn) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by jak2, calr, or mpl mutations. |
2021-01-25 |
2023-08-13 |
Not clear |
| Ayalew Teffer. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. American journal of hematology. vol 93. issue 12. 2019-08-19. PMID:30039550. |
primary myelofibrosis (pmf) is a myeloproliferative neoplasm (mpn) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by jak2, calr, or mpl mutations; additional disease features include bone marrow stromal reaction including reticulin fibrosis, abnormal cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (emh), constitutional symptoms, cachexia, leukemic progression, and shortened survival. |
2019-08-19 |
2023-08-13 |
Not clear |
| Ayalew Teffer. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. American journal of hematology. vol 91. issue 12. 2017-06-21. PMID:27870387. |
disease overview: primary myelofibrosis (pmf) is a myeloproliferative neoplasm (mpn) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by jak2, calr or mpl mutation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (emh), constitutional symptoms, cachexia, leukemic progression and shortened survival. |
2017-06-21 |
2023-08-13 |
Not clear |
| J Mascarenhas, T I Mughal, S Verstovse. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Current medicinal chemistry. vol 19. issue 26. 2013-08-21. PMID:22830345. |
myeloproliferative neoplasms (mpn) are debilitating stem cell-derived clonal myeloid malignancies. |
2013-08-21 |
2023-08-12 |
Not clear |